ライフサイエンスコーパス: imiquimod

1 TLR-4 [lipopolysaccharide (LPS)], and TLR-7 (imiquimod).

2 and by 42 (46%; 37.2-55.3) patients assigned imiquimod.

3 psoriasis-like skin inflammation induced by imiquimod.

4 ld enhance chemokine expression initiated by imiquimod.

5 n was topically inflamed by the TLR7 agonist imiquimod.

6 s, as do sensing of viral ssRNA and the drug imiquimod.

7 topical toll-like receptor (TLR)-7 agonist, imiquimod.

8 ring mice completely abolished the effect of imiquimod.

9 by topical application of the TLR7/8 agonist imiquimod.

10 llowed by additional topical applications of imiquimod.

11 LR agonists, including the pure TLR7 agonist imiquimod.

12 l antibody blocked the protective effects of imiquimod.

13 ation of the innate immune response modifier imiquimod.

14 y topical administration of the TLR7 agonist imiquimod.

15 deoxynucleotides (ODN), or the TLR7 agonist, imiquimod.

16 Ps), LPS, and the imidazoquinoline compound, imiquimod.

17 s sense haptens, pDCs are primary sensors of imiquimod.

18 it for lesions that respond early to topical imiquimod.

19 IL-23 or by application of the TLR7 agonist imiquimod.

20 ion in response to the inflammatory mediator imiquimod.

21 by poly(I.C) of TLR3 but not of TLR7/8 with imiquimod.

22 mly allocated cidofovir and 91 were assigned imiquimod.

23 Imiquimod (1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-

24 reported previously led to the discovery of imiquimod, 26, which was developed as a topical agent an

25 A new formulation of imiquimod (3.75% cream) is recommended for AGW treatment

26 Participants were randomized to imiquimod 5% cream once daily (superficial basal cell ca

27 by centre and tumour type, to receive either imiquimod 5% cream once daily for 6 weeks (superficial)

28 Imiquimod 5% cream was effective in the treatment of AK,

29 Imiquimod, 5%, and the Mw vaccine were equally effective

30 Patients received either imiquimod, 5%, cream and an intralesional vehicle (imiqu

31 lesional Mw vaccine is comparable to that of imiquimod, 5%, in treatment of AGWs.

32 In this report, topical imiquimod, a synthetic TLR7 agonist, significantly enhan

33 Imiquimod, a TLR 7 agonist, has been found to be efficac

34 luated the safety and feasibility of topical imiquimod, a TLR7 agonist, in a series of vaccinations a

35 ated the efficacy and mechanism of action of imiquimod, a topically applied inducer of cytokines.

36 Imiquimod accelerated barrier recovery after acute insul

37 Imiquimod-activated chemokine expression was dependent u

38 Continuous imiquimod administration in CNS tumor-bearing mice, howe

39 We additionally demonstrated that imiquimod administration significantly increased the acc

40 roduction in the epidermis following topical imiquimod administration to murine skin.

41 a more robust inflammatory response than did imiquimod after inoculation into the CNS, with higher le

42 with TLR3 [Poly(I:C)], TLR4 (LPS), and TLR7 (imiquimod) agonists showed decreased proliferation and a

43 Imiquimod (Aldara 5% cream; 3M Pharmaceuticals, St Paul,

44 atment for the first 4 recipients of topical imiquimod, all of whom displayed a marked improvement of

45 APCs from mice treated with UV irradiation, imiquimod alone or the combination of UV irradiation and

46 were significantly enhanced in poly (I: C), imiquimod along with inactivated PRRSV group.

47 Imiquimod also enhanced DNA repair of UV light (UVL)-irr

48 SCCs treated in vitro with imiquimod also expressed vascular E-selectin.

49 Imiquimod also increased interleukin-8 concentrations in

50 In vivo and in vitro treatment with imiquimod also induced IL-6 production by effector T cel

51 However, both CpG ODN and imiquimod also induced proinflammatory cytokine expressi

52 Imiquimod, an immune response modifier, has been demonst

53 topically with available anti-cancer drugs (imiquimod and 5-fluorouracil).

54 Imiquimod and CL097 inhibited the quinone oxidoreductase

55 Recently, a combination therapy of imiquimod and GV has shown an inhibitory effect against

56 In contrast, two other adjuvants, imiquimod and Quil A saponin, favored an expansion of an

57 R7 and TLR9, responded to imidazoquinolines (imiquimod and R-848) and to CpG oligodeoxynucleotides st

58 e of mice and rats to topical application of imiquimod and S-28463 and also to evaluate these agents

59 In vitro, both imiquimod and S-28463 induced increases in interferon an

60 These results demonstrate that imiquimod and S-28463 stimulate production of cytokines

61 r TNF-alpha in response to the TLR7 agonists imiquimod and Sendai virus and to the TLR9 agonist CpG.

62 s of 83.6% (178/213) and 98.4% (185/188) for imiquimod and surgery, respectively.

63 rs in only 2 cases, and the immunomodulators imiquimod and thalidomide allowed 5 patients to reach su

64 the mechanism of inflammasome activation by imiquimod and the related molecule CL097 and determined

65 e examined the potential of the TLR7 agonist imiquimod and the TLR9 agonist cytosine-phosphate-guanos

66 alpha following stimulation with TLR7 ligand imiquimod and TLR9 ligand CpG ODN-2216 was also impaired

67 tively isolated CLL cells by using anti-IgM, imiquimod, and CpG oligodeoxynucleotide for BCR, TLR7, a

68 were challenged with Aldara, which contains imiquimod, and is used as an experimental model to induc

69 Imiquimod, and its analogs R-842, S-27609, and S-28463,

70 Potent pDC-activating stimuli, such as CpG, imiquimod, and Sendai virus, induced the most Tim-3 expr

71 Imiquimod, another topical immunomodulator, approved for

72 stimulated in aged murine skin with topical imiquimod application.

73 These data suggest that topical imiquimod applications may play a role in preventing UV-

74 tial virus immune globulin, palivizumab, and imiquimod are discussed, as well new uses of acyclovir,

75 mune modifiers tacrolimus, pimecrolimus, and imiquimod as well as intravenous immunoglobulin.

76 munomodulators tacrolimus, pimecrolimus, and imiquimod, as well as intravenous Ig.

77 ity of two topical treatments--cidofovir and imiquimod--as an alternative to surgery in female patien

78 current studies, the topical application of imiquimod at the site of subcutaneously injected Plasmod

79 rstand the immunological mechanisms by which imiquimod augmented antitumor immunity, we tested whethe

80 nt of donor-derived DCs to the skin, whereas imiquimod augmented their alloreactivity.

81 SCC treated with imiquimod before excision contained dense T-cell infiltr

82 d with the Toll-like receptor (TLR)7 agonist imiquimod before excision showed induction of E-selectin

83 t TGF-beta, enhanced the antitumor effect of imiquimod by significantly prolonging survival in treate

84 onstrate that treatment with the TLR7 ligand imiquimod can inhibit Th1 and Th17 cells, resulting in t

85 that topical treatment with a TLR-7 agonist, imiquimod, can elicit significant regression of spontane

86 esolve inflammation after discontinuation of imiquimod challenge.

87 duction by Vgamma4(+) gammadeltaT cells upon imiquimod challenge.

88 d modest clinical 3-year benefit for topical imiquimod compared with surgery for superficial or nodul

89 nce occurred in 50% of patients treated with imiquimod, compared to 5% treated with vehicle, and the

90 however, neonatal TNF-alpha responses to the imiquimod congener R-848 (TLR 7/8) were fully intact.

91 adjunctive treatment with the TLR-7 agonist imiquimod could augment antitumor immune responsiveness

92 skin inflammation by topical treatment with imiquimod cream (Aldara).

93 ALDARA (imiquimod cream 5%) recently became available for the tr

94 treatment for low-risk basal-cell carcinoma, imiquimod cream might still be a useful treatment option

95 tly, topical treatment of mouse skin with 5% imiquimod cream prior to UVL irradiation resulted in a d

96 We aimed to assess the effectiveness of imiquimod cream versus surgical excision in patients wit

97 Treatment of primary melanomas with 5% imiquimod cream was associated with an increase in both

98 Imiquimod cream, 5%, was applied topically to a designat

99 primary melanoma biopsy site with placebo or imiquimod cream, we measured immune responses in the tre

100 Application of imiquimod cream, whether initiated at the time of cell i

101 rmore, CP-456,773 reduces ear swelling in an imiquimod cream-induced mouse model of skin inflammation

102 (polyinosinic-polycytidylic acid) or MyD88 (imiquimod), demonstrating selectivity for C5a regulation

103 nescent, in vivo imaging, we determined that imiquimod dramatically enhanced both the persistence and

104 a simple linear peptide followed by topical imiquimod elicited strong Th1 CD4(+) T-cell responses, a

105 support the idea that TLR7 agonists such as imiquimod enhance DNA repair in bone marrow-derived cell

106 Imiquimod enhanced the expression of xeroderma pigmentos

107 To test our hypothesis that imiquimod enhances DNA repair as a mechanism for its ant

108 nociceptors, DDCs failed to produce IL-23 in imiquimod-exposed skin.

109 Although topical imiquimod exposures before UV light did not prevent the

110 Upon skin challenge with imiquimod, eYFP(+) gammadelta and CD4 T cells expanded i

111 1 participants were randomly assigned to the imiquimod group (n=254) or the surgical excision group (

112 nalysis, 59% (n = 26) of the patients in the imiquimod group and 67% (n = 30) of those in the Mw grou

113 vents in 99 (40%) of 249 participants in the imiquimod group and 97 (42%) of 229 in the surgery group

114 ents in the cidofovir group and seven in the imiquimod group either withdrew or were lost to follow-u

115 rse events were itching (211 patients in the imiquimod group vs 129 in the surgery group) and weeping

116 years, 178 (84%) of 213 participants in the imiquimod group were treated successfully compared with

117 12 (5%) participants in the imiquimod group withdrew because of adverse events compa

118 4 x 108 copies/mg of tissue; P = .01) in the imiquimod group.

119 mod, 5%, cream and an intralesional vehicle (imiquimod group: 44 patients) or vehicle cream and intra

120 TLR7 activation by imiquimod has pleiotropic effects on innate immune cells

121 Imiquimod has TLR7-independent activities that are mecha

122 Indeed, synthetic TLR agonists such as imiquimod have already established utility in treating v

123 ments, only photodynamic therapy and topical imiquimod have become established treatments for specifi

124 and improvement in warts in combination with imiquimod; however, immunoglobulin levels and specific v

125 l carcinoma (PNBCC) following treatment with imiquimod (IMQ) has not yet been established.

126 aining the Toll-like receptor (TLR)7 agonist Imiquimod (IMQ) onto patients induces flares of psoriasi

127 Following exposure to the inflammatory agent imiquimod (IMQ) the Vgamma4(+) subset of gammadeltaT cel

128 d that short-term, 5-7 d-long application of imiquimod (IMQ), a TLR7 agonist, to the skin of mice tri

129 e model of psoriasis induced by TLR7 agonist imiquimod (IMQ), we show that VISTA deficiency exacerbat

130 Similarly, the imiquimod (IMQ)- and Il23-induced mouse psoriasis was as

131 Similarly, MCPIP1 was overexpressed in the imiquimod (IMQ)-driven mouse model of cutaneous inflamma

132 -1KO) mice and wild-type (WT) controls in an imiquimod (IMQ)-induced murine model of psoriasis.

133 lysaccharide (LPS)-induced keratinocytes and imiquimod (IMQ)-induced psoriasiform dermatitis in mice.

134 elta or PI3Kgamma are largely protected from imiquimod (IMQ)-induced psoriasis-like dermatitis, corre

135 her macrophages are activated in the skin of imiquimod (IMQ)-treated mice, a model for IL-17A-induced

136 At a functional level, both TLR7/8- (imiquimod [IMQ]) and TLR9-stimulated (CpG2216) pDCs lyse

137 ain samples identified significant levels of Imiquimod in both compartments at molar concentrations l

138 safety and objective response rate (ORR) of imiquimod in combination with systemic albumin bound pac

139 al, and systemic immune responses induced by imiquimod in patients with high-risk melanoma.

140 L-12 was important in the protective role of imiquimod in preventing UV-induced loss of CHS, as syste

141 ther evidence for a TLR7-independent role of imiquimod in the epithelial immune response and reinforc

142 Topical application of imiquimod in vivo led to epidermal microabscess formatio

143 kin lesions induced by daily applications of imiquimod in wild-type mice were almost totally absent i

144 Particular local adverse events with imiquimod included erythema (27%), scabbing or crusting

145 one or the combination of UV irradiation and imiquimod indicated the same in vivo synergy between imi

146 Treatment of normal human skin with imiquimod induced activation of resident T cells and red

147 The TLR7 agonist imiquimod induced astrocyte activation and up-regulation

148 Inhibition of imiquimod induced cytokine production required residues

149 Compared with untreated skin, topical imiquimod induced dermal mononuclear cell infiltrates in

150 is using tumor-derived RNA demonstrated that imiquimod induced high levels of IL-10 in addition to TN

151 elta T cells and CD8(+) Tc17 cells; 2) block imiquimod-induced cutaneous inflammation; 3) inhibit Th1

152 ibited significantly reduced inflammation in imiquimod-induced dermatitis, and were resistant to indu

153 eficient (Il36r-/-) mice were protected from imiquimod-induced expansion of dermal IL-17-producing ga

154 d was associated with reduced rhinovirus and imiquimod-induced IFN responses by these cells compared

155 muli, and that CP-456,773 inhibits R848- and imiquimod-induced IL-1beta release.

156 lutely required for IL-22 production because imiquimod-induced IL-22 expression in the skin is still

157 phenotype, as well as the transcriptome, of imiquimod-induced inflammation in human skin resembles a

158 stemic treatment with ustekinumab diminished imiquimod-induced inflammation.

159 Using an imiquimod-induced model of immune-mediated epidermal hyp

160 cultures, in vitro migration assays, and the imiquimod-induced model of psoriasiform skin inflammatio

161 ICZ reduced the inflammatory response in the imiquimod-induced model of skin inflammation and AhR-def

162 g miR-146a(-/-) mice in conjunction with the imiquimod-induced mouse model of psoriasis.

163 Imiquimod-induced psoriasiform dermatitis was exacerbate

164 t-induced steatohepatitis on the severity of imiquimod-induced psoriasiform dermatitis.

165 The severity of imiquimod-induced psoriasiform inflammation was greatly

166 sively demonstrated using the mouse model of imiquimod-induced psoriasiform skin lesions.

167 In an imiquimod-induced psoriasis model, the administration of

168 at in mice via TMP778 administration reduced imiquimod-induced psoriasis-like cutaneous inflammation.

169 e primary keratinocyte cell cultures and the imiquimod-induced psoriasis-like mouse model of skin inf

170 ing genetically modified mice, we found that imiquimod-induced psoriasis-like skin inflammation was c

171 Using an imiquimod-induced psoriasis-like skin model, we show tha

172 cal roles of CIKS/Act1-mediated signaling in imiquimod-induced psoriatic inflammation, a mouse model

173 ling IL-22 during skin inflammation, we used imiquimod-induced skin disease in rodents and showed tha

174 In contrast, tapinarof has no impact on imiquimod-induced skin inflammation in AhR-deficient mic

175 t source of IL-17 in acute murine IL-23- and imiquimod-induced skin inflammation, in human psoriasis

176 Whereas IL-17C promoted inflammation in an imiquimod-induced skin-inflammation model, it exerted pr

177 ferred substantially reduced BLP-, LPS-, and imiquimod-induced TNF-alpha release on adult monocytes w

178 We demonstrate that imiquimod induces a monomorphic and self-limited inflamm

179 In human subjects imiquimod induces contact dermatitis with the distinctiv

180 Treatment of T reg cells in vitro with imiquimod inhibited their suppressive activity and reduc

181 The demonstration that local application of imiquimod inhibits vascular tumor enlargement in the mou

182 Imiquimod (IQ) is an agonist of Toll-like receptor 7 (TL

183 d indicated the same in vivo synergy between imiquimod irradiation and UV irradiation in enhancing IL

184 Imiquimod is a cream-formulated, TLR7 agonist that is Fo

185 Imiquimod is a small-molecule ligand of Toll-like recept

186 Imiquimod is a synthetic compound with antitumor propert

187 Imiquimod is a synthetic Toll-like receptor 7 (TLR7) ago

188 Imiquimod is a TLR agonist that is used as an antitumor

189 Imiquimod is a TLR7/8 agonist that has anticancer therap

190 Imiquimod is a topical immune response modifier and Toll

191 The antitumor effect of imiquimod is multifactorial, although its ability to mod

192 however, the topical mechanism of action of imiquimod is not fully understood.

193 eptor 7/8 by means of topical application of imiquimod is the most commonly used mouse model of psori

194 ontaining the Toll-like receptor 7/8 agonist Imiquimod, is a widely used mouse model for investigatin

195 Imiquimod leads to an 80-100% cure rate of lentigo malig

196 our hypothesis that topical applications of imiquimod may protect the skin immune system against the

197 ex I inhibition and endolysosomal effects of imiquimod might also contribute to NLRP3 activation.

198 ired for psoriasis-like lesions in the mouse imiquimod model and is produced by both T cells and inna

199 Despite these shortcomings, the human imiquimod model might be useful to investigate early pat

200 Nevertheless, the imiquimod model mimics the hallmarks of psoriasis.

201 ing innate-like T cell populations in a TLR7 imiquimod model of psoriasis-like disorder, indicating t

202 The imiquimod model requires careful consideration and warra

203 3-induced ear swelling model and the topical imiquimod model, and significantly reduced the number of

204 tion and thickness in both the Rac1(V12) and imiquimod mouse models of psoriasis.

205 the systemic immune response induced by the imiquimod/NY-ESO-1 combination, and show that it elicite

206 treated with poly (I: C) of TLR3 ligand and imiquimod of TLR7 ligand, along with inactivated PRRSV a

207 immune-response modifier that is similar to imiquimod, on recurrent herpes simplex virus (HSV) was e

208 a gel in a 10 g tube, to last 6 weeks) or 5% imiquimod (one 250 mg sachet for every application), to

209 n C57BL/6 mice (PASI score of 1) compared to imiquimod-only treatment (PASI score of 4).

210 parable to Tacrolimus but markedly less than imiquimod-only treatment.

211 se, and secreted cytokines after exposure to imiquimod or lipopolysaccharide.

212 ics develop exacerbated psoriasis induced by imiquimod or recombinant IL-23 injection when challenged

213 Topical administration of imiquimod or S-28463 to the flanks of hairless mice and

214 of mice after topical application of either imiquimod or S-28463.

215 a Toll-like receptor 4 (TLR4) (EM005), TLR7 (imiquimod), or TLR9 (CpG DNA) agonist during immunizatio

216 Since 2009, the imiquimod- or Aldara-induced (3M Pharmaceuticals, St. Pa

217 o harm for one additional adverse event with imiquimod over 12-16 weeks ranged from 3.2 to 5.9.

218 ught to investigate the potential of a human imiquimod patch test model to resemble human psoriasis.

219 The results suggest that imiquimod positively influences DC trafficking and the p

220 protein was administered intradermally into imiquimod preconditioned sites followed by additional to

221 -derived immature DC injected into adjuvant (Imiquimod)-pretreated sites in cancer patients acquired

222 into adjuvant (Adjuprime, poly-arginine, or Imiquimod)-pretreated skin exhibited lymph node migrator

223 CpG oligonucleotides and imiquimod, prototypic drugs in this category, are now kn

224 The TLR7 agonist imiquimod (R837) caused rapid dose-dependent relaxation

225 ially blocked the TLR-7-activating effect of imiquimod (R837), while transfection with the NS4B gene

226 Treatment of mice with 5% imiquimod resulted in synergistic reduction in CNS tumor

227 Imiquimod's adjuvant effects require further evaluation

228 Skin biopsies were assessed for imiquimod's in situ immunomodulatory effects.

229 In vitro imiquimod stimulated production of IL-1alpha and neutrop

230 TLR7 was essential for imiquimod-stimulated pDCs to produce IFN-alpha/beta, whi

231 Thus, imiquimod stimulates tumor destruction by recruiting cut

232 mmation induced by the TLR7 receptor agonist imiquimod subtly yet reproducibly decreases time to skin

233 7.7% (173/177) for surgery (relative risk of imiquimod success = 0.84, 95% confidence interval = 0.77

234 gues demonstrate that topical application of imiquimod suppresses cutaneous melanoma by TLR7-dependen

235 adverse event was substantially higher with imiquimod than with vehicle, and numbers needed to harm

236 for NLRP3 activation and identify targets of imiquimod that might be clinically relevant.

237 dofovir and 39 (46%) of 84 patients assigned imiquimod; the most frequent grade 3 and 4 events were p

238 -mediated effects, we studied the effects of imiquimod therapy on effector T cells infiltrating human

239 However, tumor growth progressed once imiquimod therapy was ended.

240 Although surgery is clearly superior to imiquimod, this study shows sustained benefit for lesion

241 iquimod, TLR7, and as such are stimulated by imiquimod through a novel pathway.

242 HPV16 virus-like particles and treated with imiquimod (TLR7 agonist).

243 tes do not express the putative receptor for imiquimod, TLR7, and as such are stimulated by imiquimod

244 grew poorly in bovine cells pretreated with imiquimod to stimulate interferon production.

245 sted the efficacy of topical applications of imiquimod to treat patients afflicted with this chronic

246 deltaT17 cells homed normally to the skin of imiquimod-treated CCR6(-/-) mice.

247 Additionally, only imiquimod-treated mice were resistant to hapten-specific

248 he major source of IL-22 in lymph nodes from imiquimod-treated mice.

249 lating IL-10 were also detected in sera from imiquimod-treated mice.

250 In the vaginal mucosa of imiquimod-treated monkeys, we documented a massive monon

251 -selectin expression at levels comparable to imiquimod-treated SCCs undergoing immunologic destructio

252 vo and the mechanism of their recruitment to imiquimod-treated sites have never been demonstrated.

253 gammadeltaT17 cells were greatly reduced in imiquimod-treated skin of CCR6(-/-) mice, but adoptively

254 Imiquimod-treated tumors contained a decreased percentag

255 Imiquimod-treated tumors showed decreased tumor cell pro

256 igorous IFN-gamma production than did either imiquimod-treated XS52 or UV-irradiated XS52, again sugg

257 Imiquimod-treated, UV-irradiated XS52 triggered a more v

258 ocedure, and 16 were offered radiotherapy or imiquimod treatment as a consequence of the RCM findings

259 mented antitumor immunity, we tested whether imiquimod treatment enhanced DC function or the priming

260 Most imiquimod treatment failures occurred in year 1.

261 Our results demonstrate that imiquimod treatment leads to CCL2-dependent recruitment

262 Topical imiquimod treatment led to TLR7-dependent and IFN-alpha/

263 Thus, topical imiquimod treatment of anogenital warts led to significa

264 s small pilot study demonstrate that topical imiquimod treatment results in enhanced local and region

265 Additionally, the combination of imiquimod treatment with prior vaccination led to develo

266 major role in neutrophil infiltration after imiquimod treatment.

267 regulatory cells, which were also induced by imiquimod treatment.

268 cuminata clear during topical treatment with imiquimod, wart skin biopsies were taken from patients b

269 tosis (AK) with the immune response modifier imiquimod was assessed using published randomized-contro

270 Imiquimod was inferior to surgery according to our prede

271 to R-848, a TLR ligand that is a congener of imiquimod, was equivalent in newborn and adult blood.

272 Five-year success rates for imiquimod were 82.5% (170/206) compared with 97.7% (173/

273 Cidofovir and imiquimod were active, safe, and feasible for treatment

274 We exposed the skin of mice to imiquimod, which induces IL-23-dependent psoriasis-like

275 A synthetic TLR7 agonist, imiquimod, which is FDA approved for topical treatment o

276 after topical application of the TLR7 ligand imiquimod, which is known to enhance the LC emigration f

277 Indeed, the association of Imiquimod with the brain correlated with increased Iba1

278 eliorated psoriasiform dermatitis induced by imiquimod, with decreased pro-inflammatory IL-17- and IL